Diego Cadavid, MD of Fulcrum Therapeutics provides an update on the Phase 2 Clinical Trial testing the safety and efficacy of losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD).
FSHD is a rare, progressive musculoskeletal disease in which persons initially lose muscle strength in the face, shoulders, arms, and trunk, but later the disease progresses throughout the lower body. FSHD is due to the mis-expression of DUX4 in skeletal muscles. Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.
Currently, a phase 2 clinical trial in underway, and the trial design has been adjusted to accommodate COVID-19 and will also include outcome measures that are of clinical relevance to the FSHD community. Results from the trial are expected in 2021.
To learn more about FSHD and other rare musculoskeletal conditions, visit checkrare.com/diseases/musculoskeletal-diseases/